Development of an ErbB4 monoclonal antibody that blocks neuregulin-1-induced ErbB4 activation in cancer cells

Shogo Okazaki, Fumi Nakatani, Kazue Masuko, Kenji Tsuchihashi, Shiho Ueda, Takashi Masuko, Hideyuki Saya, Osamu Nagano

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

The use of monoclonal antibodies (mAbs) for cancer therapy is one of the most important strategies for current cancer treatment. The epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases, which regulates cancer cell proliferation, survival, and migration, is a major molecular target for antibody-based therapy. ErbB4/HER4, which contains a ligand-binding extracellular region, is activated by several ligands, including neuregulins (NRGs), heparin-binding EGF-like growth factor, betacellulin and epiregulin. Although there are clinically approved antibodies for ErbB1 and ErbB2, there are no available therapeutic mAbs for ErbB4, and it is not known whether ErbB4 is a useful target for antibody-based cancer therapy. In this study, we developed an anti-ErbB4 mAb (clone P6-1) that suppresses NRG-dependent activation of ErbB4 and examined its effect on breast cancer cell proliferation in the extracellular matrix.

Original languageEnglish
Pages (from-to)239-244
Number of pages6
JournalBiochemical and Biophysical Research Communications
Volume470
Issue number1
DOIs
Publication statusPublished - 2016 Jan 29

Keywords

  • Breast cancer
  • ErbB4
  • Neuregulin
  • Neutralizing antibody
  • Three-dimensional culture

ASJC Scopus subject areas

  • Biochemistry
  • Biophysics
  • Cell Biology
  • Molecular Biology

Fingerprint Dive into the research topics of 'Development of an ErbB4 monoclonal antibody that blocks neuregulin-1-induced ErbB4 activation in cancer cells'. Together they form a unique fingerprint.

  • Cite this